Provided by Tiger Trade Technology Pte. Ltd.

Stoke Therapeutics, Inc.

30.89
-0.3100-0.99%
Volume:727.50K
Turnover:22.47M
Market Cap:1.99B
PE:-9.27
High:31.38
Open:29.94
Low:29.94
Close:31.20
52wk High:40.22
52wk Low:18.80
Shares:64.53M
Float Shares:49.01M
Volume Ratio:0.78
T/O Rate:1.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3325
EPS(LYR):-0.1163
ROE:-61.10%
ROA:-35.87%
PB:5.77
PE(LYR):-265.69

Loading ...

Stoke Therapeutics Says Phase 3 Emperor Trial of Dravet Drug Zorevunersen is Underway, Results Due Q3 2027

Reuters
·
Yesterday

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16TH European Epilepsy Congress (Eec)

THOMSON REUTERS
·
Yesterday

U.S. Stocks on the MOVE-Ubiquiti, BJ's Wholesale, Arbutus

Reuters
·
Aug 21

J.P. Morgan Resumes Coverage on Stoke Therapeutics with 'overweight'; Shares Rise

Reuters
·
Aug 21

Is Stoke Therapeutics (STOK) A Bargain On Its EMPEROR Trial Enrollment Milestone?

Simply Wall St.
·
Aug 19

Stoke Therapeutics Grants New Hires Options for 70,950 Shares at $32.13 Each

Reuters
·
Aug 19

Analysts Have Made A Financial Statement On Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Second-Quarter Report

Simply Wall St.
·
Aug 06

Lexicon Pharmaceuticals Posts Q2 Net Loss

Reuters
·
Aug 06

Stoke Therapeutics CMO Barry Ticho Disposes of USD 208,707 in Common Shares

Reuters
·
Aug 06

Stoke Therapeutics to Present at Canaccord Genuity Annual Growth Conference

Reuters
·
Aug 05

EyePoint Pharmaceuticals Q2 Revenue Drops on Lower License Income

Reuters
·
Aug 05

Entrada Therapeutics Q2 Net Loss Narrows on Lower Costs

Reuters
·
Aug 05

Kymera Therapeutics Q2 Collaboration Revenue More than Doubles, Beats Estimates

Reuters
·
Aug 05

Niagen Bioscience Q2 Net Sales Fall, Missing Estimates

Reuters
·
Aug 05

Analysts Are Bullish on These Healthcare Stocks: Stoke Therapeutics (STOK), Fortrea Holdings Inc. (FTRE)

TIPRANKS
·
Aug 04

Stoke Therapeutics Files for At-the-Market Offering of up to $200 Million in Stock

Reuters
·
Aug 04

Stoke Therapeutics - May Offer up to $200 Mln in Common Stock - SEC Filing

THOMSON REUTERS
·
Aug 04

Stoke Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 04

Stoke Therapeutics Q2 Revenue Falls 33% on Lower Collaboration, Licensing Income

Reuters
·
Aug 04

Stoke Therapeutics Q2 FY26 Net Loss Widens to $61.62 Million; Revenue Falls to $9.33 Million

Reuters
·
Aug 04